[S02DA03, antipyrine, The metabolism of Encorafenib can be decreased when combined with Antipyrine.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Encorafenib.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Encorafenib.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Encorafenib.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Encorafenib.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Encorafenib.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Encorafenib.]
[A04AD10, dronabinol, The metabolism of Encorafenib can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Encorafenib.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Encorafenib.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Encorafenib.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Encorafenib.]
[C01BB04, aprindine, The metabolism of Encorafenib can be decreased when combined with Aprindine.]
[B01AC05, ticlopidine, The metabolism of Encorafenib can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Encorafenib.]
[N02AX02, tramadol, The metabolism of Encorafenib can be decreased when combined with Tramadol.]
[N06AF04, tranylcypromine, The metabolism of Encorafenib can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Encorafenib.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Encorafenib.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Encorafenib.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Encorafenib.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Encorafenib.]
[R06AC04, tripelennamine, The metabolism of Encorafenib can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Encorafenib.]
[J01FA08, troleandomycin, The metabolism of Encorafenib can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Encorafenib can be decreased when combined with Vilazodone.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Vandetanib.]
[L02BX03, abiraterone, The metabolism of Encorafenib can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Encorafenib can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Encorafenib can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Encorafenib can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Encorafenib can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Encorafenib.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Encorafenib.]
[C08DA01, verapamil, The metabolism of Encorafenib can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Encorafenib can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Encorafenib can be decreased when combined with Vinblastine.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Encorafenib can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Vemurafenib.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Encorafenib.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Encorafenib.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Ziprasidone.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Encorafenib.]
[C07AB03, atenolol, The metabolism of Encorafenib can be decreased when combined with Atenolol.]
[J02AC03, voriconazole, The metabolism of Encorafenib can be decreased when combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Encorafenib.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Encorafenib.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Encorafenib.]
[A08AA11, lorcaserin, The metabolism of Encorafenib can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Encorafenib can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Encorafenib can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Encorafenib can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Encorafenib can be decreased when it is combined with Enzalutamide.]
[J05AE04, nelfinavir, The metabolism of Encorafenib can be decreased when combined with Nelfinavir.]
[N06DA02, donepezil, The metabolism of Encorafenib can be decreased when combined with Donepezil.]
[G04BD10, darifenacin, The metabolism of Encorafenib can be decreased when combined with Darifenacin.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Encorafenib.]
[G04BE03, sildenafil, The metabolism of Encorafenib can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Encorafenib.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Encorafenib.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Encorafenib.]
[A10BH04, alogliptin, The metabolism of Encorafenib can be decreased when combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Encorafenib can be decreased when combined with Glycerol phenylbutyrate.]
[G03XC05, ospemifene, The metabolism of Encorafenib can be decreased when combined with Ospemifene.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Encorafenib.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Encorafenib.]
[A06AX06, tegaserod, The metabolism of Encorafenib can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Benzocaine.]
[M01AH01, celecoxib, The metabolism of Encorafenib can be decreased when combined with Celecoxib.]
[L04AA18, everolimus, The metabolism of Encorafenib can be decreased when combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Encorafenib.]
[L01EC02, dabrafenib, The serum concentration of Encorafenib can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The metabolism of Encorafenib can be decreased when combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Bepridil.]
[L01EL01, ibrutinib, The metabolism of Encorafenib can be decreased when combined with Ibrutinib.]
[N06AX26, vortioxetine, The metabolism of Encorafenib can be decreased when combined with Vortioxetine.]
[J05AP05, simeprevir, The metabolism of Encorafenib can be decreased when combined with Simeprevir.]
[A10BK01, dapagliflozin, The metabolism of Encorafenib can be decreased when combined with Dapagliflozin.]
[C07AB04, acebutolol, The metabolism of Encorafenib can be decreased when combined with Acebutolol.]
[A16AA07, metreleptin, The metabolism of Encorafenib can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Encorafenib can be increased when combined with Apremilast.]
[S01ED02, betaxolol, The metabolism of Encorafenib can be decreased when combined with Betaxolol.]
[L04AC11, siltuximab, The metabolism of Encorafenib can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Encorafenib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Encorafenib.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Encorafenib.]
[A16AX10, eliglustat, The metabolism of Encorafenib can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Encorafenib can be decreased when combined with Oritavancin.]
[N04AA02, biperiden, The metabolism of Encorafenib can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Encorafenib can be decreased when combined with Pirfenidone.]
[J05AP09, dasabuvir, The metabolism of Encorafenib can be decreased when combined with Dasabuvir.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Encorafenib.]
[L04AC10, secukinumab, The metabolism of Encorafenib can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Encorafenib.]
[L01XH03, panobinostat, The metabolism of Encorafenib can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Encorafenib can be decreased when combined with Acetaminophen.]
[C01EB17, ivabradine, Ivabradine may increase the QTc-prolonging activities of Encorafenib.]
[J05AP06, asunaprevir, The metabolism of Encorafenib can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The metabolism of Encorafenib can be decreased when combined with Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Encorafenib can be decreased when combined with Rolapitant.]
[A02BC03, lansoprazole, The metabolism of Encorafenib can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Encorafenib.]
[J02AC05, isavuconazole, The metabolism of Encorafenib can be decreased when combined with Isavuconazole.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Encorafenib.]
[L01XX52, venetoclax, The metabolism of Encorafenib can be decreased when combined with Venetoclax.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Encorafenib.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Encorafenib.]
[N07BC01, buprenorphine, The metabolism of Encorafenib can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Encorafenib.]
[N05BE01, buspirone, The metabolism of Encorafenib can be decreased when combined with Buspirone.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Encorafenib.]
[S01GX07, azelastine, The metabolism of Encorafenib can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Encorafenib can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Encorafenib.]
[L01EF02, ribociclib, The metabolism of Encorafenib can be decreased when combined with Ribociclib.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Encorafenib.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Oxybuprocaine.]
[J05AE09, tipranavir, The metabolism of Encorafenib can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Encorafenib.]
[L04AB02, infliximab, The metabolism of Encorafenib can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Encorafenib can be decreased when combined with Midostaurin.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Encorafenib.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Encorafenib.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Encorafenib.]
[J05AG03, efavirenz, The metabolism of Encorafenib can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The metabolism of Encorafenib can be decreased when combined with Bopindolol.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Encorafenib.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Encorafenib.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Encorafenib.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Capsaicin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Encorafenib.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Encorafenib can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Encorafenib can be increased when combined with Carbamazepine.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Encorafenib.]
[C07AG02, carvedilol, The metabolism of Encorafenib can be decreased when combined with Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Encorafenib can be decreased when combined with Cannabidiol.]
[S01AA13, fusidic acid, The metabolism of Encorafenib can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Encorafenib.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Encorafenib.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Encorafenib.]
[L01XX62, ivosidenib, The metabolism of Encorafenib can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Encorafenib can be decreased when combined with Tafenoquine.]
[N03AX17, stiripentol, The metabolism of Encorafenib can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Encorafenib.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Encorafenib.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Chloroprocaine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Encorafenib.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Encorafenib.]
[L04AA39, emapalumab, The metabolism of Encorafenib can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Encorafenib.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Encorafenib.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Encorafenib.]
[P02BX04, triclabendazole, The metabolism of Encorafenib can be decreased when combined with Triclabendazole.]
[J01FA09, clarithromycin, The metabolism of Encorafenib can be decreased when combined with Clarithromycin.]
[N05BA09, clobazam, The metabolism of Encorafenib can be decreased when combined with Clobazam.]
[L04AB01, etanercept, The metabolism of Encorafenib can be increased when combined with Etanercept.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Encorafenib.]
[L01EJ02, fedratinib, The metabolism of Encorafenib can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Encorafenib can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Encorafenib.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Encorafenib.]
[G04BE04, yohimbine, The metabolism of Encorafenib can be decreased when combined with Yohimbine.]
[N03AX25, cenobamate, The serum concentration of Encorafenib can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Encorafenib can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Encorafenib.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Dexchlorpheniramine.]
[M01AX21, diacetylrhein, The metabolism of Encorafenib can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Encorafenib.]
[H02CA02, osilodrostat, The metabolism of Encorafenib can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Encorafenib can be decreased when combined with Amprenavir.]
[N02AA08, dihydrocodeine, The metabolism of Encorafenib can be decreased when combined with Dihydrocodeine.]
[N02CC06, eletriptan, The metabolism of Encorafenib can be decreased when combined with Eletriptan.]
[C08CA16, clevidipine, The metabolism of Encorafenib can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Encorafenib can be decreased when combined with Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Encorafenib.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Encorafenib.]
[G04BD09, trospium, The metabolism of Encorafenib can be decreased when combined with Trospium.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Dyclonine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Encorafenib.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Encorafenib.]
[P01BB01, proguanil, The metabolism of Encorafenib can be decreased when combined with Proguanil.]
[L04AC19, satralizumab, The serum concentration of Encorafenib can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The metabolism of Oliceridine can be decreased when combined with Encorafenib.]
[P01BA01, chloroquine, The metabolism of Encorafenib can be decreased when combined with Chloroquine.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Encorafenib.]
[N05AA01, chlorpromazine, The metabolism of Encorafenib can be decreased when combined with Chlorpromazine.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Encorafenib.]
[M03BB03, chlorzoxazone, The metabolism of Encorafenib can be decreased when combined with Chlorzoxazone.]
[A11CC05, cholecalciferol, The metabolism of Encorafenib can be decreased when combined with Cholecalciferol.]
[B06AC06, berotralstat, The metabolism of Encorafenib can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Encorafenib can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Encorafenib.]
[P03AX07, abametapir, The serum concentration of Encorafenib can be increased when it is combined with Abametapir.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Encorafenib.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Encorafenib.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Encorafenib.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Encorafenib.]
[L03AB10, peginterferon alfa-2b, The metabolism of Encorafenib can be decreased when combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The metabolism of Encorafenib can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Encorafenib.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Encorafenib.]
[L01XX73, sotorasib, The serum concentration of Encorafenib can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Encorafenib.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Citalopram.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Encorafenib is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Clemastine.]
[N06AX25, St. John's wort extract, The metabolism of Encorafenib can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Encorafenib can be decreased when combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Encorafenib.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Encorafenib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Encorafenib.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Encorafenib.]
[C01EB24, mavacamten, The serum concentration of Encorafenib can be decreased when it is combined with Mavacamten.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Encorafenib.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Encorafenib.]
[N05AH02, clozapine, The metabolism of Encorafenib can be decreased when combined with Clozapine.]
[H01AC08, somatrogon, The metabolism of Encorafenib can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Encorafenib can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The metabolism of Encorafenib can be decreased when combined with Codeine.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Encorafenib.]
[A10BX03, nateglinide, The metabolism of Encorafenib can be decreased when combined with Nateglinide.]
[J01FA15, telithromycin, The metabolism of Encorafenib can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Encorafenib can be decreased when combined with Ciclesonide.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Encorafenib.]
[N02CC05, almotriptan, The metabolism of Encorafenib can be decreased when combined with Almotriptan.]
[J02AC02, itraconazole, The metabolism of Encorafenib can be decreased when combined with Itraconazole.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Encorafenib.]
[L01EA01, imatinib, The serum concentration of Encorafenib can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Encorafenib can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Encorafenib.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Encorafenib.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Encorafenib.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Encorafenib.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Encorafenib.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Encorafenib.]
[C08CA11, manidipine, The metabolism of Encorafenib can be decreased when combined with Manidipine.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Encorafenib.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Encorafenib.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Encorafenib.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Encorafenib.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Melperone is combined with Encorafenib.]
[N06AX07, minaprine, The metabolism of Encorafenib can be decreased when combined with Minaprine.]
[S01XA18, cyclosporine, The metabolism of Encorafenib can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Encorafenib can be decreased when combined with Moclobemide.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Encorafenib.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Encorafenib.]
[C03XA02, conivaptan, The metabolism of Encorafenib can be decreased when combined with Conivaptan.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Encorafenib.]
[M01AH05, etoricoxib, The metabolism of Encorafenib can be decreased when combined with Etoricoxib.]
[G03XA01, danazol, The metabolism of Encorafenib can be decreased when combined with Danazol.]
[C02CC04, debrisoquin, The metabolism of Encorafenib can be decreased when combined with Debrisoquine.]
[C07AB12, nebivolol, The metabolism of Encorafenib can be decreased when combined with Nebivolol.]
[N06AX06, nefazodone, The metabolism of Encorafenib can be decreased when combined with Nefazodone.]
[N06AB10, escitalopram, The serum concentration of Encorafenib can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Encorafenib.]
[N06AA01, desipramine, The metabolism of Encorafenib can be decreased when combined with Desipramine.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Encorafenib.]
[S03BA01, dexamethasone, The metabolism of Encorafenib can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Encorafenib can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Encorafenib can be decreased when combined with Dexfenfluramine.]
[L04AB04, adalimumab, The metabolism of Encorafenib can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Encorafenib can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The metabolism of Encorafenib can be decreased when combined with Amphetamine.]
[R05DA09, dextromethorphan, The metabolism of Encorafenib can be decreased when combined with Dextromethorphan.]
[N06AB05, paroxetine, The metabolism of Encorafenib can be decreased when combined with Paroxetine.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Cinchocaine.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Encorafenib.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Encorafenib.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Encorafenib.]
[C08CA03, isradipine, The metabolism of Encorafenib can be decreased when combined with Isradipine.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Encorafenib.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Encorafenib.]
[J05AE08, atazanavir, The metabolism of Encorafenib can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Encorafenib.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Encorafenib.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Encorafenib.]
[M02AX03, dimethyl sulfoxide, The metabolism of Encorafenib can be decreased when combined with Dimethyl sulfoxide.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Diphenhydramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Cisapride.]
[N05AL04, remoxipride, The metabolism of Encorafenib can be decreased when combined with Remoxipride.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Encorafenib.]
[S02AA12, rifamycin SV, The metabolism of Encorafenib can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Encorafenib can be increased when combined with Rifapentine.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Encorafenib.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Encorafenib.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Encorafenib.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Encorafenib.]
[A04AD12, aprepitant, The metabolism of Encorafenib can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Encorafenib.]
[C01EB18, ranolazine, The serum concentration of Encorafenib can be increased when it is combined with Ranolazine.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Encorafenib.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Domperidone.]
[N06AA16, dothiepin, The metabolism of Encorafenib can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Encorafenib.]
[L01DB01, doxorubicin, The metabolism of Encorafenib can be decreased when combined with Doxorubicin.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Encorafenib.]
[N06AB06, sertraline, The metabolism of Encorafenib can be decreased when combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Encorafenib.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Encorafenib.]
[C10AA01, simvastatin, The metabolism of Encorafenib can be decreased when combined with Simvastatin.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Sultopride.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Encorafenib.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Temafloxacin.]
[D01BA02, terbinafine, The metabolism of Encorafenib can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Terodiline.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Encorafenib.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Encorafenib.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Toremifene.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Encorafenib.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Encorafenib.]
[L01CA04, vinorelbine, The metabolism of Encorafenib can be decreased when combined with Vinorelbine.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Encorafenib.]
[N06AX16, venlafaxine, The metabolism of Encorafenib can be decreased when combined with Venlafaxine.]
[C08CA12, mepirodipine, The metabolism of Encorafenib can be decreased when combined with Barnidipine.]
[N05CF02, zolpidem, The metabolism of Encorafenib can be decreased when combined with Zolpidem.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Encorafenib.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Encorafenib.]
[N02CA02, ergotamine, The metabolism of Encorafenib can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Encorafenib.]
[H05BX01, cinacalcet, The metabolism of Encorafenib can be decreased when combined with Cinacalcet.]
[J04AK02, ethambutol, The metabolism of Encorafenib can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The metabolism of Encorafenib can be decreased when combined with Fluvastatin.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Encorafenib.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Meloxicam.]
[S01XA06, ethylmorphine, The metabolism of Encorafenib can be decreased when combined with Ethylmorphine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Etidocaine.]
[N05AE03, sertindole, The metabolism of Encorafenib can be decreased when combined with Sertindole.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Encorafenib.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Encorafenib.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Encorafenib.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Encorafenib.]
[R06AX12, terfenadine, The metabolism of Encorafenib can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Encorafenib can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Encorafenib can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Encorafenib.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Encorafenib.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Encorafenib.]
[C08CA02, felodipine, The metabolism of Encorafenib can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Fendiline is combined with Encorafenib.]
[N03AX26, fenfluramine, The metabolism of Encorafenib can be decreased when combined with Fenfluramine.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Encorafenib.]
[N07AX03, cevimeline, The metabolism of Encorafenib can be decreased when combined with Cevimeline.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Encorafenib.]
[J02AC01, fluconazole, The metabolism of Encorafenib can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The metabolism of Encorafenib can be decreased when combined with Flunarizine.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Encorafenib.]
[N06AB03, fluoxetine, The serum concentration of Encorafenib can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Flupentixol.]
[N05AB02, fluphenazine, The metabolism of Encorafenib can be decreased when combined with Fluphenazine.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Encorafenib.]
[J05AE10, darunavir, The metabolism of Encorafenib can be decreased when combined with Darunavir.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Encorafenib.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Encorafenib.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Encorafenib.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Encorafenib.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Encorafenib.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Encorafenib.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Encorafenib.]
[N05CM18, dexmedetomidine, The metabolism of Encorafenib can be decreased when combined with Dexmedetomidine.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Dofetilide.]
[C02CA04, doxazosin, The metabolism of Encorafenib can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Encorafenib.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Encorafenib.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Encorafenib.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Encorafenib.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Encorafenib.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Encorafenib.]
[J05AG01, nevirapine, The metabolism of Encorafenib can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Encorafenib.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Encorafenib.]
[P01BA02, hydroxychloroquine, The metabolism of Encorafenib can be decreased when combined with Hydroxychloroquine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Hydroxyzine.]
[L01DB06, idarubicin, The metabolism of Encorafenib can be decreased when combined with Idarubicin.]
[N06AA02, imipramine, The metabolism of Encorafenib can be decreased when combined with Imipramine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Encorafenib.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Encorafenib.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Encorafenib.]
[N06AX17, milnacipran, The metabolism of Encorafenib can be decreased when combined with Milnacipran.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Articaine.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Encorafenib.]
[C10AA06, cerivastatin, The metabolism of Encorafenib can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Anagrelide.]
[C07AA01, alprenolol, The metabolism of Encorafenib can be decreased when combined with Alprenolol.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Encorafenib.]
[N06AF05, iproniazid, The metabolism of Encorafenib can be decreased when combined with Iproniazid.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Encorafenib.]
[N04BX02, entacapone, The metabolism of Encorafenib can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Encorafenib can be decreased when combined with Isoniazid.]
[N06AX18, reboxetine, The metabolism of Encorafenib can be decreased when combined with Reboxetine.]
[L04AC07, tocilizumab, The metabolism of Encorafenib can be increased when combined with Tocilizumab.]
[J02AB02, ketoconazole, The metabolism of Encorafenib can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Encorafenib can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Encorafenib.]
[L04AA24, abatacept, The metabolism of Encorafenib can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Mizolastine.]
[N04BC09, rotigotine, The metabolism of Encorafenib can be decreased when combined with Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Encorafenib.]
[C07AG01, labetalol, The metabolism of Encorafenib can be decreased when combined with Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Encorafenib.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Encorafenib.]
[N02CA07, lisuride, The metabolism of Encorafenib can be decreased when combined with Lisuride.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Loperamide is combined with Encorafenib.]
[C10AA02, lovastatin, The metabolism of Encorafenib can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The metabolism of Encorafenib can be decreased when combined with Temsirolimus.]
[L01EA03, nilotinib, The metabolism of Encorafenib can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Encorafenib.]
[R06AE05, meclizine, The metabolism of Encorafenib can be decreased when combined with Meclizine.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Encorafenib.]
[N03AB04, mephenytoin, The metabolism of Encorafenib can be decreased when combined with Mephenytoin.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Mepivacaine.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Encorafenib.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Encorafenib.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Methadone is combined with Encorafenib.]
[N06BA03, methamphetamine, The metabolism of Encorafenib can be decreased when combined with Metamfetamine.]
[H03BB02, methimazole, The metabolism of Encorafenib can be decreased when combined with Methimazole.]
[N05AA02, methotrimeprazine, The metabolism of Encorafenib can be decreased when combined with Methotrimeprazine.]
[N02BG09, methoxyflurane, The metabolism of Encorafenib can be decreased when combined with Methoxyflurane.]
[V04CG05, methylene blue, The metabolism of Encorafenib can be decreased when combined with Methylene blue.]
[A03FA01, metoclopramide, The metabolism of Encorafenib can be decreased when combined with Metoclopramide.]
[C07AB02, metoprolol, The metabolism of Encorafenib can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Encorafenib.]
[C01BB02, mexiletine, The metabolism of Encorafenib can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The metabolism of Encorafenib can be decreased when combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Encorafenib can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Encorafenib can be decreased when combined with Aminophenazone.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Mifepristone.]
[L01XX23, mitotane, The metabolism of Encorafenib can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The metabolism of Encorafenib can be decreased when combined with Lisdexamfetamine.]
[C01BD01, amiodarone, The metabolism of Encorafenib can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Encorafenib.]
[A04AA05, palonosetron, The metabolism of Encorafenib can be decreased when combined with Palonosetron.]
[L04AB05, certolizumab pegol, The metabolism of Encorafenib can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Encorafenib.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Encorafenib.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Encorafenib.]
[N03AB05, fosphenytoin, The metabolism of Encorafenib can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, The metabolism of Encorafenib can be decreased when combined with Nadolol.]
[V03AB15, naloxone, The metabolism of Encorafenib can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Encorafenib can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The metabolism of Encorafenib can be decreased when combined with Amphetamine.]
[N06AX21, duloxetine, The metabolism of Encorafenib can be decreased when combined with Duloxetine.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Encorafenib.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Encorafenib.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Iloperidone.]
[N06AX23, desvenlafaxine, The metabolism of Encorafenib can be decreased when combined with Desvenlafaxine.]
[C10AD02, niacin, The metabolism of Encorafenib can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Encorafenib can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Encorafenib can be decreased when combined with Nicergoline.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Encorafenib.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Encorafenib.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Encorafenib.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Encorafenib.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Encorafenib.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Encorafenib.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Encorafenib.]
[L04AC04, rilonacept, The metabolism of Encorafenib can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Encorafenib can be decreased when combined with Omeprazole.]
[N02AA02, opium, The metabolism of Encorafenib can be decreased when combined with Opium.]
[G04CA02, tamsulosin, The metabolism of Encorafenib can be decreased when combined with Tamsulosin.]
[P02BA02, oxamniquine, The metabolism of Encorafenib can be decreased when combined with Oxamniquine.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Encorafenib.]
[C07AA02, oxprenolol, The metabolism of Encorafenib can be decreased when combined with Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Encorafenib can be decreased when combined with Oxycodone.]
[N02AA11, oxymorphone, The metabolism of Encorafenib can be decreased when combined with Oxymorphone.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Encorafenib.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Asenapine.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Encorafenib.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Encorafenib.]
[G04BD11, fesoterodine, The metabolism of Encorafenib can be decreased when combined with Fesoterodine.]
[C07AA23, penbutolol, The metabolism of Encorafenib can be decreased when combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Penfluridol.]
[N05CA01, pentobarbital, The metabolism of Encorafenib can be increased when combined with Pentobarbital.]
[C08EX02, perhexiline, The metabolism of Encorafenib can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The metabolism of Encorafenib can be decreased when combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Encorafenib can be decreased when combined with Phenacetin.]
[A10BA01, phenformin, The metabolism of Encorafenib can be decreased when combined with Phenformin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Encorafenib.]
[N03AA02, phenobarbital, The metabolism of Encorafenib can be increased when combined with Phenobarbital.]
[N03AB02, phenytoin, The metabolism of Encorafenib can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Encorafenib can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Encorafenib.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Encorafenib.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Encorafenib.]
[C07AA03, pindolol, The metabolism of Encorafenib can be decreased when combined with Pindolol.]
[J05AE01, saquinavir, The metabolism of Encorafenib can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Encorafenib can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The metabolism of Encorafenib can be decreased when combined with Pipotiazine.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Encorafenib can be decreased when combined with Delavirdine.]
[L04AC08, canakinumab, The metabolism of Encorafenib can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Encorafenib can be increased when it is combined with Ritonavir.]
[C07AB01, practolol, The metabolism of Encorafenib can be decreased when combined with Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Encorafenib.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Encorafenib.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Encorafenib.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Encorafenib can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Encorafenib can be increased when combined with Primidone.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Encorafenib.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Encorafenib.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Procaine.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Encorafenib.]
[G03DA04, progesterone, The metabolism of Encorafenib can be decreased when combined with Progesterone.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Promazine is combined with Encorafenib.]
[R06AD02, promethazine, The metabolism of Encorafenib can be decreased when combined with Promethazine.]
[C01BC03, propafenone, The metabolism of Encorafenib can be decreased when combined with Propafenone.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Encorafenib.]
[N02AC04, propoxyphene, The metabolism of Encorafenib can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The metabolism of Encorafenib can be decreased when combined with Propranolol.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Encorafenib.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Encorafenib.]
[R06AC01, pyrilamine, The metabolism of Encorafenib can be decreased when combined with Mepyramine.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Quinidine.]
[P01BC01, quinine, The metabolism of Encorafenib can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Encorafenib can be decreased when combined with Ranitidine.]
[J04AB02, rifampin, The metabolism of Encorafenib can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Encorafenib.]
[N04BD01, selegiline, The metabolism of Encorafenib can be decreased when combined with Selegiline.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Encorafenib.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Valproic acid.]
